New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 6, 2014
08:44 EDTTINYHarris & Harris notes Metabolon's collaboration agreement with HLI
Harris & Harris notes the announcement by its portfolio company, Metabolon, that it has signed an agreement with newly-launched Human Longevity Inc., or HLI, whereby Metabolon will provide biochemical profiling services to assist HLI in its mission to address diseases of aging by building the world's largest and most complete human genotype, microbiome and phenotype database. In the initial term of the agreement, Metabolon will perform small molecule analysis of 10,000 subjects and collaborate with HLI to map changes in the small molecules to end points of disease and gene mutations. Under the agreement, Metabolon will apply its metabolomics technology to augment the genetic and microbiome information HLI is collecting. Metabolon's approach identifies the complement of metabolites present in a human biological specimen. Metabolomics is important because quantifying and understanding the full picture of circulating biochemicals in the body can help researchers get a clearer picture of that individual's health status and provide markers and pathways associated with disease and drug action. In addition, Metabolon will collaborate with HLI to identify small molecule biomarkers of disease, which Metabolon may then use to develop small molecule diagnostic tests.
News For TINY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 3, 2016
09:32 EDTTINYHarris & Harris, Mersana Therapeutics, expand partnership with Technip
Harris & Harris notes the announcement by its portfolio company, Mersana Therapeutics, that Mersana and Takeda Pharmaceutical have entered a new strategic partnership granting Takeda rights to Mersana's lead product candidate, XMT-1522, outside the United States and Canada. The deal also expands an existing collaboration between the companies to provide Takeda with additional access to Mersana's Fleximer antibody-drug conjugate, or ADC, platform and grants Mersana an option at the end of Phase 1 to co-develop and co-commercialize one of these programs in the United States. In addition, the companies will co-develop new payloads for use with ADCs. XMT-1522 is an investigational, Fleximer-based ADC therapy that targets HER2-expressing tumors, including breast, gastric and non-small cell lung cancers. Mersana will receive an upfront payment of $40M and an additional payment of $20M upon clearance of the IND for XMT-1522 by the FDA. Subject to the success of the XMT-1522 and ADC programs, Mersana is eligible to receive milestone payments of more than $750 million combined, as well as royalties. Takeda will also invest up to $20M in equity in future rounds of Mersana financing.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use